Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
Earnings Data
Report Date
Mar 02, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.79Last Year’s EPS
-1.11Same Quarter Last Year
Moderate Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive progress in clinical trials and strategic partnerships, but was overshadowed by significant financial challenges, including revenue decline and increased net loss. The indefinite delay in the Costave BLA filing represents a major hurdle for the company's commercial prospects in the US market.Company Guidance
ARCT032 Phase II Clinical Trial Progress
Interim data from the Phase II clinical trial of ARCT032 for cystic fibrosis showed that the treatment was generally safe and well tolerated. A protocol pre-specified analysis using AI technology revealed reductions in mucus burden in four out of six participants in the second cohort.
ARCT810 Program Advancements
Positive interim Phase II data for ARCT810, a therapeutic candidate for ornithine transcarbamylase deficiency, with plans for regulatory meetings in 2026 to discuss pivotal trial strategy.
Partnership with Meiji Seika Pharma
Launch of the two-dose vial of Costave updated for the JN1 variant XE in Japan, marking the first distribution of this presentation in the country.
Financial Position and Cost Reductions
Arcturus reported a strong financial position with a cash runway extended into 2028 due to planned cost reductions and strategic focus on key therapeutic programs.
ARCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ARCT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 10, 2025 | $8.78 | $8.67 | -1.25% |
Aug 11, 2025 | $11.39 | $14.89 | +30.73% |
May 12, 2025 | $11.59 | $11.86 | +2.33% |
Mar 06, 2025 | $15.97 | $14.55 | -8.89% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Arcturus Therapeutics (ARCT) report earnings?
Arcturus Therapeutics (ARCT) is schdueled to report earning on Mar 02, 2026, After Close (Confirmed).
What is Arcturus Therapeutics (ARCT) earnings time?
Arcturus Therapeutics (ARCT) earnings time is at Mar 02, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARCT EPS forecast?
ARCT EPS forecast for the fiscal quarter 2025 (Q4) is -0.79.
